Sumitomo Dainippon Pharma Annual Report 2017
71/102

Thousands of sharesMillions of yenAccumulated other comprehensive income (loss)Shareholders’ equitySee Notes to Consolidated Financial Statements.Issuednumber ofshares ofcommonstockNumberoftreasurystocksCommonstockCapitalsurplusRetainedearnings Treasurystock Totalshare-holders’equityUnrealizedgains (losses)on available-for-salesecurities Deferredgains(losses)on hedgesForeigncurrencytranslationadjustmentsRemeasure-ments ofdenedbenetplansTotalaccumulatedothercomprehensiveincome (loss)Total netassets (596)(3)0(599)(599)(2)0(601)¥ 22,400¥ 22,400¥ 22,40022,400¥ 22,400¥ 15,8601¥ 15,861¥ 15,86115,8610¥ 15,861¥ 326,686(7,152)24,697(5)(2,824)¥ 341,402¥ 341,402386341,788(7,151)28,991¥ 363,628¥ (660)(3)0¥ (663)¥ (663) (663)(4)0¥ (667)¥ 23,0992,194¥ 25,293¥ 25,293(192)25,101(6,661)¥ 18,440¥ 2(15)¥ (13)¥ (13)(13)(7)¥ (20)¥ 68,171(20,146)¥ 48,025¥ 48,02548,025(2,297)¥ 45,728¥ (4,537)(1,295)¥ (5,832)¥ (5,832)(5,832)1,119¥ (4,713)¥ 451,021(7,152)24,697(3)1(5)(2,824)(19,262)¥ 446,473¥ 446,473194446,667(7,151)28,991(4)0(7,846)¥ 460,657Thousands of U.S. dollars (Note 1)Accumulated other comprehensive income (loss)Shareholders’ equityCommonstockCapitalsurplusRetainedearnings Treasurystock Totalshare-holders’equityUnrealizedgains (losses)on available-for-salesecurities Deferredgains(losses)on hedgesForeigncurrencytranslationadjustmentsRemeasure-ments ofdenedbenetplansTotalaccumulatedothercomprehensiveincome (loss)Total netassets $ 200,000200,000 $ 200,000$ 141,616141,6160 $ 141,616$ 3,048,2323,4463,051,678(63,848)258,848 $ 3,246,678$ (5,919)(5,919)(36)0$ (5,955)$ 3,383,9293,4463,387,375(63,848)258,848(36)0 $ 3,582,339$ 225,830(1,714)224,116(59,473)$ 164,643$ (116)(116)(63)$ (179)$ 428,795428,795(20,509)$ 408,286$ (52,071)(52,071)9,991$ (42,080)$ 602,438(1,714)600,724(70,054)$ 530,670$ 3,986,3671,7323,988,099(63,848)258,848(36)0(70,054)$ 4,113,009BALANCE, APRIL 1, 2015Cash dividends, ¥18.00 per share Net income attributable to owners of the parentPurchases of treasury stock Sales of treasury stock Change of scope of equity methodDecrease due to change in scal period of consolidated subsidiariesNet change in items other than shareholders’ equityBALANCE, MARCH 31, 2016BALANCE, APRIL 1, 2016Cumulative effects of changes in accounting policies.Restated balanceCash dividends, ¥18.00 per share Net income attributable to owners of the parentPurchases of treasury stock Sales of treasury stock Change of scope of equity methodDecrease due to change in scal period of consolidated subsidiariesNet change in items other than shareholders’ equityBALANCE, MARCH 31, 2017Financial SectionConsolidated Statements of Changes in Net AssetsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016¥ 364,286(7,152)24,697(3)1(5)(2,824)¥ 379,000¥ 379,000386379,386(7,151)28,991(4)0¥ 401,222¥ 86,735(19,262)¥ 67,473¥ 67,473(192)67,281(7,846)¥ 59,435397,900397,900397,900397,900BALANCE, APRIL 1, 2016Cumulative effects of changes in accounting policies.Restated balanceCash dividends, U.S.$ 0.16 per shareNet income attributable to owners of the parentPurchases of treasury stockSales of treasury stockChange of scope of equity methodDecrease due to change in scal period of consolidated subsidiariesNet change in items other than shareholders’ equity BALANCE, MARCH 31, 201770Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#71

このブックを見る